Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family
Open accessThe DOI matches its Crossref record.
Abstract
J. Neurochem. (2011) 118, 490–498. A substantial body of data was reported between 1984 and 2000 demonstrating that the neuropeptide N‐acetylaspartylglutamate (NAAG) not only functions as a neurotransmitter but also is the third most prevalent transmitter in the mammalian nervous system behind glutamate and GABA. By 2005, this conclusion was validated further through a series of studies in vivo and in vitro. The primary enzyme responsible for the inactivation of NAAG following its synaptic release had been cloned, characterized and knocked out. Potent inhibitors of this enzyme were developed and their efficacy has been extensively studied in a series of animal models of clinical conditions, including stroke, peripheral neuropathy, traumatic brain injury, inflammatory and neuropathic pain, cocaine addiction, and schizophrenia. Considerable progress also has been made in defining further the mechanism of action of these peptidase inhibitors in elevating synaptic levels of NAAG with the consequent inhibition of transmitter release via the activation of pre‐synaptic metabotropic glutamate receptor 3 by this peptide. Very recent discoveries include identification of two different nervous system enzymes that mediate the synthesis of NAAG from N‐acetylaspartate and glutamate and the finding that one of these enzymes also mediates the synthesis of a second member of the NAAG family of neuropeptides, N‐acetylaspartylglutamylglutamate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
Bukke, V. N., Archana, M., Villani, R., Romano, A. D., Wawrzyniak, A., Balawender, K., Orkisz, S., Beggiato, S., Serviddio, G., & Cassano, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207452 · Cited by 161
Adapting brain metabolism to myelination and long‐range signal transduction
Hirrlinger, J., & Nave, K. (2014) · Glia · doi:10.1002/glia.22737 · Cited by 109
“NAAG is hydrolyzed to NAA and glutamate (which will itself activate glutamate receptors) by glutamate-carboxy-peptidase-II (GCPII) located on the surface of astrocytes (Berger et al., 1999; Neale et al., 2011).”
BackgroundMiyanishi, H., & Nitta, A. (2021) · Pharmaceuticals · doi:10.3390/ph14090889 · Cited by 57
“NAAG is widely present in the brains of mammals [143] and functions as a highly selective neurotransmitter for group II metabotropic glutamate receptor 3 (mGluR3) [144].”
BackgroundFriedman, S. D., Baker, L. D., Borson, S., Jensen, J. E., Barsness, S. M., Craft, S., Merriam, G. R., Otto, R. K., Novotny, E. J., & Vitiello, M. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1425 · Cited by 52
Metadata
- Authors
- Neale, J. H., Olszewski, R. T., Zuo, D., Janczura, K. J., Profaci, C. P., Lavin, K. M., Madore, J. C., & Bzdega, T.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2011-07
- Volume
- 118
- Issue
- 4
- Pages
- 490-498
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1729884812
- Cited by
- 95
- References
- 0
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. https://app.cochat.ai/papers/10.1111/j.1471-4159.2011.07338.x
- The paper
- Neale, J. H., Olszewski, R. T., Zuo, D., Janczura, K. J., Profaci, C. P., Lavin, K. M., Madore, J. C., & Bzdega, T. (2011). Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2011.07338.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.